Phenotypes associated with this allele

• Allele Symbol: Gt(ROSA)26Sor^{tm1(EWSR1/FLI1)Sbk}
• Allele Name: targeted mutation 1, Suzanne J Baker
• Allele ID: MGI:3769110
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Gt(ROSA)26Sor^tm1(EWSR1/FLI1)Sbk/Gt(ROSA)26Sor^+ Tg(Mx1-cre)1Cgn/?	involves: 129S1/Sv * C57BL/6 * CBA	MGI:3769116

Genotype
MGI:3769116

cn1

• Allelic Composition: Gt(ROSA)26Sor^{tm1(EWSR1/FLI1)Sbk}/Gt(ROSA)26Sor⁺; Tg(Mx1-cre)1Cgn/?
• Genetic Background: involves: 129S1/Sv * C57BL/6 * CBA

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:129039 )

• when treated at day 2 or 3 with pIpC, the median age of death is 16 days with distended abdomens, pale footpads, hunched posture, and ruffled fur

• untreated mice exhibit a median age of death of 95 days do to the leakiness of the cre transgene

hematopoietic system

enlarged spleen ( J:129039 )

• when treated at day 2 or 3 with pIpC, spleens are 12.8-fold larger than wild-type due to increased proliferation without decreased apoptotic rates

abnormal blood cell morphology/development ( J:129039 )

• when treated at day 2 or 3 with pIpC, blood smears contain an abnormal presence of immature blast cells

abnormal myelopoiesis ( J:129039 )

• when treated at day 2 or 3 with pIpC, red pulp is expanded with immature myeloid cells that are 30% to 50% positive for stem cell markers

anemia ( J:129039 )

• when treated at day 2 or 3 with pIpC, mice develop severe anemia

decreased erythrocyte cell number ( J:129039 )

• 2.1+/-0.5x10⁶ per ul compared to 6.4+/-1.5x10⁶ per ul in wild-type mice when treated at day 2 or 3 with pIpC

decreased hematocrit ( J:129039 )

• 15+/-3% compared to 37+/-7% in wild-type mice when treated at day 2 or 3 with pIpC

thrombocytosis ( J:129039 )

• 515+/-223x10³ per ul compared to 399+/-149x10³ per ul in wild-type mice when treated at day 2 or 3 with pIpC

increased leukocyte cell number ( J:129039 )

• 90+/-68x10³ per ul compared to 3.4+/-1.5x10³ per ul in wild-type mice when treated at day 2 or 3 with pIpC

increased spleen red pulp amount ( J:129039 )

• when treated at day 2 or 3 with pIpC, red pulp is expanded with immature myeloid cells that are 30% to 50% positive for stem cell markers

neoplasm

increased leukemia incidence ( J:129039 )

• when treated at day 2 or 3 with pIpC, mice develop leukemias and when transplanted into recipient mice are associated with leukemic proliferation

liver/biliary system

enlarged liver ( J:129039 )

• when treated at day 2 or 3 with pIpC, livers are 3.3-fold larger than wild-type due to increased proliferation without decreased apoptotic rates

immune system

enlarged spleen ( J:129039 )

• when treated at day 2 or 3 with pIpC, spleens are 12.8-fold larger than wild-type due to increased proliferation without decreased apoptotic rates

abnormal myelopoiesis ( J:129039 )

• when treated at day 2 or 3 with pIpC, red pulp is expanded with immature myeloid cells that are 30% to 50% positive for stem cell markers

increased leukocyte cell number ( J:129039 )

• 90+/-68x10³ per ul compared to 3.4+/-1.5x10³ per ul in wild-type mice when treated at day 2 or 3 with pIpC

increased spleen red pulp amount ( J:129039 )

• when treated at day 2 or 3 with pIpC, red pulp is expanded with immature myeloid cells that are 30% to 50% positive for stem cell markers

abnormal lymph node B cell domain morphology ( J:129039 )

• when treated at day 2 or 3 with pIpC, lymphoid follicles is decreased

growth/size/body

enlarged liver ( J:129039 )

• when treated at day 2 or 3 with pIpC, livers are 3.3-fold larger than wild-type due to increased proliferation without decreased apoptotic rates

enlarged spleen ( J:129039 )

• when treated at day 2 or 3 with pIpC, spleens are 12.8-fold larger than wild-type due to increased proliferation without decreased apoptotic rates